Genescience Pharmaceuticals Co. Ltd. has identified sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria (PKU).
Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) E542K mutant inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
China Resources Pharmaceutical Research Institute (Shenzhen) Co. Ltd. has disclosed heterocyclic compounds acting as protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Various derivatives of α-D-tocopherol (vitamin E) have shown antitumor potential by inhibiting metabolic processes in mitochondria, which nevertheless raises the risk of systemic toxicity. In an approach designed to inhibit such processes in a more targeted fashion, researchers at Yonsei University College of Medicine prepared from α-D-tocopherol a malonate derivative and a primary amide.
The DeGregorio Family Foundation, with support from the Esophageal Cancer Awareness Association, has awarded an additional $75,000 Michael F. Price Memorial Grant to support research that will provide the groundwork to advance two new drugs – SSTN-302 and SST-1034 – to a phase I clinical trial in patients with advanced upper gastrointestinal cancer.
Cyclin-dependent kinases (CDKs) are interesting targets in metastatic cancers. Oncobone Therapeutics Ltd. recently presented data on a new CDK9/13 dual inhibitor – OBP-004 – as a potential approach for treating metastatic cancers.
CDR-609 is a T-cell engager therapeutic from CDR-Life Inc. that targets Leucine-rich repeat-containing G protein-coupled receptor 5 (LGR5) with potential for treating colorectal cancer.
Qyuns Therapeutics Co. Ltd. has entered into a collaboration and license agreement with F. Hoffmann-La Roche Ltd. granting the latter the exclusive global rights to develop, manufacture and commercialize QX-031N.
Leading advances in cancer research, the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics highlighted some of the field’s most promising innovations. Parabilis Medicines Inc. and Tango Therapeutics Inc. presented their work on potential therapeutic targets that may signal significant shifts in the future of cancer treatment.
RSS
